New attack on returning melanoma: Double-Drug blitz before surgery

NCT ID NCT06365619

Summary

This study is testing if giving two immunotherapy drugs (ipilimumab and nivolumab) before surgery can help control melanoma that has come back after a patient's initial treatment. About 25 adults with high-risk, operable melanoma that returned during or shortly after their last therapy will receive two cycles of these drugs, then have standard surgery. Researchers will check if the drugs shrink the tumor before surgery and monitor side effects and long-term outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.